Literature DB >> 23583217

The role of the fallopian tube in the origin of ovarian cancer.

Britt K Erickson1, Michael G Conner, Charles N Landen.   

Abstract

Advanced cases of epithelial ovarian, primary peritoneal, and primary tubal malignancies have a relatively poor prognosis and collectively remain the most deadly of all gynecologic malignancies. Although traditionally thought of as one disease process, ongoing research suggests that there is not 1 single site or cell type from which these cancers arise. A majority of the serous tumors appear to originate from dysplastic lesions in the distal fallopian tube. Therefore, what we have traditionally considered "ovarian" cancer may in fact be tubal in origin. In this article, we will review epithelial ovarian cancer classification and genetics, theories regarding cells of origin with a focus on tubal intraepithelial carcinoma, and implications for prevention and screening.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  TP53 mutation; ovarian carcinogenesis; tubal intraepithelial carcinoma

Mesh:

Year:  2013        PMID: 23583217      PMCID: PMC3937451          DOI: 10.1016/j.ajog.2013.04.019

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  60 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

Review 2.  The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

3.  Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone.

Authors:  Jeffrey Pudney; Alison J Quayle; Deborah J Anderson
Journal:  Biol Reprod       Date:  2005-08-10       Impact factor: 4.285

Review 4.  Underlying mechanisms of ovarian cancer risk reduction after tubal ligation.

Authors:  David Cibula; Martin Widschwendter; Michael Zikan; Ladislav Dusek
Journal:  Acta Obstet Gynecol Scand       Date:  2011-04-15       Impact factor: 3.636

Review 5.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

Authors:  W Glenn McCluggage
Journal:  Pathology       Date:  2011-08       Impact factor: 5.306

6.  Inpatient hysterectomy surveillance in the United States, 2000-2004.

Authors:  Maura K Whiteman; Susan D Hillis; Denise J Jamieson; Brian Morrow; Michelle N Podgornik; Kate M Brett; Polly A Marchbanks
Journal:  Am J Obstet Gynecol       Date:  2007-11-05       Impact factor: 8.661

7.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

Review 8.  Prophylactic oophorectomy in premenopausal women and long-term health.

Authors:  Lynne T Shuster; Bobbie S Gostout; Brandon R Grossardt; Walter A Rocca
Journal:  Menopause Int       Date:  2008-09

9.  Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.

Authors:  Isaac Kinde; Chetan Bettegowda; Yuxuan Wang; Jian Wu; Nishant Agrawal; Ie-Ming Shih; Robert Kurman; Fanny Dao; Douglas A Levine; Robert Giuntoli; Richard Roden; James R Eshleman; Jesus Paula Carvalho; Suely Kazue Nagahashi Marie; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

10.  Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study.

Authors:  Marie Soegaard; Allan Jensen; Estrid Høgdall; Lise Christensen; Claus Høgdall; Jan Blaakaer; Susanne K Kjaer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  76 in total

Review 1.  Epithelial ovarian cancer - more data, more questions?

Authors:  Stefanie Aust; Dietmar Pils
Journal:  Wien Med Wochenschr       Date:  2014-11-13

2.  Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial.

Authors:  Akila Subramaniam; Christina T Blanchard; Britt K Erickson; Jeff Szychowski; Charles A Leath; Joseph R Biggio; Warner K Huh
Journal:  Obstet Gynecol       Date:  2018-07       Impact factor: 7.661

Review 3.  Immunotherapy for ovarian cancer.

Authors:  Justin M Drerup; Yang Liu; Alvaro S Padron; Kruthi Murthy; Vincent Hurez; Bin Zhang; Tyler J Curiel
Journal:  Curr Treat Options Oncol       Date:  2015-01

4.  Feasibility of prophylactic salpingectomy during vaginal hysterectomy.

Authors:  Danielle D Antosh; Rachel High; Heidi W Brown; Sallie S Oliphant; Husam Abed; Nisha Philip; Cara L Grimes
Journal:  Am J Obstet Gynecol       Date:  2017-07-20       Impact factor: 8.661

Review 5.  A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.

Authors:  Bryan Oronsky; Carolyn M Ray; Alexander I Spira; Jane B Trepel; Corey A Carter; Hope M Cottrill
Journal:  Med Oncol       Date:  2017-04-25       Impact factor: 3.064

6.  Adnexectomy at the time of vaginal hysterectomy for pelvic organ prolapse.

Authors:  Emily A Slopnick; David D Sheyn; Graham C Chapman; Sangeeta T Mahajan; Sharif El-Nashar; Adonis K Hijaz
Journal:  Int Urogynecol J       Date:  2019-05-21       Impact factor: 2.894

7.  Women's preferences for permanent contraception method and willingness to be randomized for a hypothetical trial.

Authors:  Adriana Piazza; Kelly Schwirian; Fiona Scott; Machelle D Wilson; Nikki B Zite; Mitchell D Creinin
Journal:  Contraception       Date:  2018-09-26       Impact factor: 3.375

8.  N-glycan MALDI Imaging Mass Spectrometry on Formalin-Fixed Paraffin-Embedded Tissue Enables the Delineation of Ovarian Cancer Tissues.

Authors:  Arun V Everest-Dass; Matthew T Briggs; Gurjeet Kaur; Martin K Oehler; Peter Hoffmann; Nicolle H Packer
Journal:  Mol Cell Proteomics       Date:  2016-07-13       Impact factor: 5.911

9.  Douching, Talc Use, and Risk of Ovarian Cancer.

Authors:  Nicole L Gonzalez; Katie M O'Brien; Aimee A D'Aloisio; Dale P Sandler; Clarice R Weinberg
Journal:  Epidemiology       Date:  2016-11       Impact factor: 4.822

Review 10.  Niraparib: A Review in Ovarian Cancer.

Authors:  Young-A Heo; Sean T Duggan
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.